Allogeneic stem cell transplantation for Glanzmann thrombasthenia.

Area of Science:

• Hematology
• Genetics
• Immunology

Background:

• Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding disorder affecting platelet aggregation due to glycoprotein IIb/IIIa defects.
• While typically causing mild bleeding, GT can lead to severe, life-threatening hemorrhages.
• Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative option but carries significant risks.

Observation:

• An 11-year-old female from the UAE presented with severe GT and anti-platelet alloimmunization.
• The patient had developed refractoriness to platelet transfusions.

Findings:

• The patient underwent successful HSCT using stem cells from her HLA-identical sibling.
• This treatment effectively managed her severe GT and alloimmunization.

Implications:

• HSCT can be a viable curative treatment for severe Glanzmann thrombasthenia, even in the presence of alloimmunization.
• This case highlights the successful application of HSCT in a challenging GT patient profile.
• Further research into optimizing HSCT protocols for rare bleeding disorders is warranted.